Pancreatic Cancer Research

ResearcherTokyo Medical UniversityActive in the last 2 years

Yuichi Nagakawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1169-8160; OpenAlex author ID A5079318688, A5088056414. Sources: OpenAlex.

Their work

Papers
41 (first author 6, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
202
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 3 papers · 2018: 5 papers · 2019: 2 papers · 2020: 6 papers · 2021: 2 papers · 2022: 1 paper · 2023: 4 papers · 2024: 3 papers · 2025: 4 papers · 2026: 6 papers

Papers 41

  1. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  2. Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled… Co-author DOI 10.1097/sla.0000000000006900↗
  3. Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Societ… Co-author DOI 10.1097/sla.0000000000007012↗
  4. ASO Visual Abstract: Survival Benefit of Surgery Versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18479-z↗
  5. Prognostic value of lactate dehydrogenase-to-albumin ratio in metastatic/recurrent pancreatic cancer treated with first-line gemcitabine plus nab-paclitaxel: a… Co-author DOI 10.21037/jgo-2026-0223↗
  6. Analysis of the relationship between immunological microenvironment and prognosis in pancreatic cancer. First author DOI 10.62347/wylc8512↗
  7. Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.05.006↗
  8. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  9. Survival Benefit of Surgery versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18212-w↗
  10. Failure to Rescue After Surgery for Pancreatic Cancer: A Systematic Review and Narrative Synthesis of Risk Factors and Safety Strategies. Last author DOI 10.3390/cancers17193259↗
  11. Prognostic factors based on histological categorization of desmoplastic reactions in pancreatic cancer. First author DOI 10.1002/wjs.12269↗
  12. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  13. Identification of New Potential Targets for Pancreatic Ductal Adenocarcinoma by Integrated Bioinformatic Analysis. Co-author DOI 10.21873/anticanres.17254↗
  14. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Co-author DOI 10.1002/cncr.34580↗
  15. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  16. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan P… Co-author DOI 10.1007/s00535-023-01988-7↗
  17. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  18. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Co-author DOI 10.1002/jhbp.1049↗
  19. Deep learning analysis for the detection of pancreatic cancer on endosonographic images: a pilot study. Co-author DOI 10.1002/jhbp.825↗
  20. Novel Therapeutic Method for Unresectable Pancreatic Cancer-The Impact of the Long-Term Research in Therapeutic Effect of High-Intensity Focused Ultrasound (HI… Co-author DOI 10.3390/curroncol28060409↗
  21. Precise anatomical resection based on structures of nerve and fibrous tissue around the superior mesenteric artery for mesopancreas dissection in pancreaticodu… Co-author DOI 10.1002/jhbp.725↗
  22. Clinical impact of pancreaticoduodenectomy for pancreatic cancer with resection of the secondary or later branches of the superior mesenteric vein. First author DOI 10.1002/jhbp.789↗
  23. Pre-aspiration of a large retention cyst followed by EUS-FNB for the successful diagnosis of a patient with pancreatic cancer. Last author DOI 10.1002/jhbp.836↗
  24. Safe exposure of the left renal vein during laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: anatomical variations and pitfalls. First author DOI 10.1007/s00595-020-02053-z↗
  25. A nomogram to preoperatively predict 1-year disease-specific survival in resected pancreatic cancer following neoadjuvant chemoradiation therapy. Co-author DOI 10.21147/j.issn.1000-9604.2020.01.12↗
  26. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data. Co-author DOI 10.3389/fonc.2020.01112↗
  27. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializi… Co-author DOI 10.1245/s10434-018-07131-8↗
  28. ASO Author Reflections: Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer: Is Combined Radiotherapy Necessary? Co-author DOI 10.1245/s10434-019-07245-7↗
  29. Surgical Outcomes of Pancreaticoduodenectomy for Pancreatic Cancer with Proximal Dorsal Jejunal Vein Involvement. First author DOI 10.1007/s11605-018-3722-0↗
  30. Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer. Co-author DOI 10.1159/000494382↗
  31. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomize… Co-author DOI 10.1186/s13063-018-3002-z↗
  32. Irreversible Electroporation for Nonthermal Tumor Ablation in Patients with Locally Advanced Pancreatic Cancer: Initial Clinical Experience in Japan. Co-author DOI 10.2169/internalmedicine.0861-18↗
  33. Elevated Polyamines in Saliva of Pancreatic Cancer. Co-author DOI 10.3390/cancers10020043↗
  34. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic … Co-author DOI 10.1007/s00280-017-3288-7↗
  35. Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection. First author DOI 10.1159/000449041↗
  36. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination. Co-author DOI 10.3390/ijms18040767↗
  37. Feasibility of intensity-modulated radiotherapy combined with gemcitabine and S-1 for patients with pancreatic cancer. Co-author DOI 10.3892/mco.2015.664↗
  38. ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2014.623↗
  39. Pancreaticoduodenectomy with right-oblique posterior dissection of superior mesenteric nerve plexus is logical procedure for pancreatic cancer with extrapancre… Co-author PMID 25699385↗
  40. Single nucleotide polymorphism of multidrug-resistance 1 and anti- multidrug-resistance 1 single chain antibody treatment for the pancreatic cancer cell line. Co-author DOI 10.5754/hge11377↗
  41. Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism an… Co-author DOI 10.5754/hge11729↗

Closest collaborators

The 25 strongest of 202 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sohei Satoi · 10 shared papers, 2018–2026 · strength 1.46
  2. Takao Itoi · 11 shared papers, 2012–2026 · strength 1.29
  3. Michiaki Unno · 8 shared papers, 2019–2026 · strength 1.25
  4. Akihiko Tsuchida · 16 shared papers, 2012–2022 · strength 1.21
  5. Tsutomu Fujii · 7 shared papers, 2018–2026 · strength 0.94
  6. Atsushi Sofuni · 7 shared papers, 2012–2026 · strength 0.87
  7. Hiroki Yamaue · 6 shared papers, 2018–2026 · strength 0.78
  8. Yoshifumi Takeyama · 5 shared papers, 2023–2025 · strength 0.75
  9. Mitsugi Shimoda · 4 shared papers, 2018–2026 · strength 0.75
  10. Masayuki Sho · 5 shared papers, 2018–2026 · strength 0.72
  11. Hidetoshi Eguchi · 5 shared papers, 2018–2026 · strength 0.69
  12. Shuji Suzuki · 3 shared papers, 2024–2026 · strength 0.67
  13. Marc G. Besselink · 4 shared papers, 2022–2026 · strength 0.65
  14. Seiko Hirono · 4 shared papers, 2018–2026 · strength 0.61
  15. Manabu Kawai · 4 shared papers, 2018–2026 · strength 0.61
  16. Kenichiro Uemura · 3 shared papers, 2023–2026 · strength 0.60
  17. Yuichi Hosokawa · 8 shared papers, 2014–2020 · strength 0.59
  18. Masaji Tani · 4 shared papers, 2018–2025 · strength 0.54
  19. Ryoichi Miyamoto · 2 shared papers, 2024–2026 · strength 0.51
  20. Toshitaka Nagao · 2 shared papers, 2024–2026 · strength 0.51
  21. Itaru Endo · 4 shared papers, 2019–2025 · strength 0.47
  22. Yu Takahashi · 3 shared papers, 2022–2026 · strength 0.47
  23. Ryosuke Tonozuka · 5 shared papers, 2017–2021 · strength 0.46
  24. Yoshiya Yamauchi · 1 shared paper, 2026 · strength 0.43
  25. Keiko Kamei · 2 shared papers, 2026 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.